The immunoasive profile of leukemia predicts the benefits of drug resistance and immunotherapy.

By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), the researchers identified a new immune category for the disease, which can predict the possibility of drug resistance and positive response to immunotherapy.their compilation of immune spectrum in AML enables clinicians to develop targeted and personalized immunotherapy programs for patients who need to respond to standard chemotherapy resistance.AML may be difficult to treat because the malignant disease has multiple molecular and immune status, and not all patients respond to the same type of intervention.immunotherapy has been studied as a potential treatment for patients with chemotherapy resistance, but clinicians lack tools to predict which type of patients will have the best response to immune regulation.to overcome this information gap, Jayakumar vadakekolathu and colleagues studied 442 bone marrow samples from three groups of 370 AML patients.the authors first found that most of the samples could be divided into two immune subtypes: immune infiltrating subtype or immune depleted subtype.by comparing their observations with established disease categories in the European leukemia network, scientists were able to predict which patients will have the highest survival rate and will be most responsive to treatment.an important finding is that patients with higher IFN - γ gene expression are more likely to respond to fleetuzumab's experimental immunotherapy; interestingly, the activity of IFN - γ can also predict the possibility of drug resistance to chemotherapeutic agents.vadakekolathu et al. Concluded that T-cell targeted therapy can be further evaluated as a novel treatment for IFN - γ - dominant AML patients.welcome to Science official account click below to read the original text.